Outlook TherapeuticsOTLK -8.04%11 EBITDA Margin % is -11,021.26% as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 945 Biotechnology companies, Outlook Therapeutics ranks worse than 95.24% on this metric.
Outlook Therapeutics (NAS:OTLK) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Outlook Therapeutics EBITDA Margin % Related Terms
Outlook Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Outlook Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTLK vs INO, CBUS, RANI: EBITDA Margin % Comparison
For the Biotechnology subindustry, Outlook Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Outlook Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Outlook Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics (OTLK) has a EBITDA Margin % of -11,021.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Outlook Therapeutics and its competitors. According to the industry distribution chart, Outlook Therapeutics ranks #900 out of 945 companies in the Biotechnology industry, placing it in the top 95.2%.
Is Outlook Therapeutics' EBITDA Margin % too high?
Outlook Therapeutics' current EBITDA Margin % is -11,021.26%. Based on the distribution chart, Outlook Therapeutics ranks #900 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' EBITDA Margin % compare to INO and CBUS?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #900 out of 945 companies for EBITDA Margin %. This places Outlook Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current EBITDA Margin % is -11,021.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current EBITDA Margin % of -11,021.26%. The current EBITDA Margin % is -11,021.26%. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current EBITDA Margin % is -11,021.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score
Get the complete analysis for OTLK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLK has been successfully added to your 
